Diabetes

Listen to 2 obesity experts discuss the impact of the COVID-19 pandemic on obesity-related type 2 diabetes.

ADA 2023. Results from PIONEER PLUS trial showed oral semaglutide 25 mg and 50 mg were superior than 14 mg in reducing HbA1c and body weight in adults with T2D.

Your daily dose of clinical news you may have missed.

ADA 2023: SURMOUNT-2 findings show tirzepatide is associated with greater weight loss in adults with T2D than any other treatment studied to date.

Type 2 diabetes will continue to comprise more than 90% of this population and obesity will be the primary driver, according to Global Burden of Disease researchers.

ADA 2023. Retatrutide, an investigational triple GLP-1/GIP/glucagon agonist, may provide benefits in liver fibrosis and obesity as well as in glycemic control.

SGLT-2 inhibitors were found to consistently reduce risk of CV mortality and HF events in a meta-analysis including 90 000 high-risk patients with T2D, CKD, and/or HF.

Early intervention is important to reduce the risk for complications for patients with obesity and type 2 diabetes. Two obesity experts explain more, here.

The 2 SGLT-2 inhibitor-based medications are the first in the class to be approved for pediatric T2D and provide a much needed additional oral treatment option for the population.

Eden Miller, DO, shares key takeaways on how personalized treatment helps in the management of diabetes.

Elizabeth Holt, MD, FACE, and Eden Miller, DO, comment on the pros and cons of real-world data studies, looking particularly at the study of the OneTouch Verio Flex meter and the OneTouch Reveal apps.

Experts discuss steps to introduce the OneTouch Verio Flex meter and the OneTouch Reveal app to patients to better manage diabetes.

ENDO 2023. The pattern of intermittent fasting improved glycemic measures in a weight-independent fashion after just 7 days, according to the study abstract.

Your daily dose of clinical news you may have missed.

Finerenone was associated with a decrease in composite CV risk in patients with CKD, T2D, eGFR of ≥25, and moderately to severely increased albuminuria.

Your daily dose of clinical news you may have missed.

Nearly half of responding medical professionals said patients without T2D have asked for an Ozempic Rx and about 18% of them have provided one, avoiding significant backlash for a denial.

Your daily dose of clinical news you may have missed.

Patients with diabetes had a 35% higher risk of COPD compared with those without diabetes, according to new research.

Try this 7-question quiz on the 2023 guidelines from The Endocrine Society that focus on advances in diabetes treatment that help minimize risk of hypoglycemia.

More research is needed to determine whether metformin is also effective in patients with lower body mass index or with previous infection, said researchers.

Eden Miller, DO, reviews the impact the BGM and diabetes management apps have on the patient, giving clinicians a better ability to personalize treatment and empower the patient.

Experts discuss how the amount of time a patient spends engaging with the BGM and diabetes apps will contribute to managing their diabetes.

Prescriptions for continuous glucose monitoring for patients with T2D are increasing, a new study finds, and the authors report on characteristics of new CGM users.

Reduced risk for 10 different cancers was reported among patients with diabetes treated with SGLT2 inhibitors compared with those not treated.